» Articles » PMID: 32554858

Long Noncoding RNA LINC00963 Induces NOP2 Expression by Sponging Tumor Suppressor MiR-542-3p to Promote Metastasis in Prostate Cancer

Overview
Specialty Geriatrics
Date 2020 Jun 20
PMID 32554858
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic disease caused by castration-resistant prostate cancer (CRPC) is the principal cause of prostate cancer (PCa)-related mortality. CRPC occurs within 2-3 years of initiation of androgen deprivation therapy (ADT), which is an important factor of influencing PCa metastasis. Recent studies have revealed that non-coding RNAs in PCa can enhance metastasis and progression, while the mechanisms are still unclear. In this study, we reported that the long noncoding RNA-LINC00963 was increased in CRPC tissues and promoted migration of PCa cells in vitro and their metastasis in vivo. High levels of LINC00963 significantly decreased tumor suppressor miR-542-3p, whose levels in metastasis tissues were low compared to those in non-metastasis tissues. LINC00963 promotes and miR-542-3p inhibits metastasis. Furthermore, the expression levels of LINC00963 and miR-542-3p were positively and negatively associated with the expression of NOP2. We demonstrated that NOP2 promoted PCa by activating the epithelial-mesenchymal transition (EMT) pathway. For specific mechanism, dual luciferase reporter assays showed that miR-542-3p directly binds to both 3'-untranslated region (UTR) of LINC00963 and NOP2 mRNA. Taken together, our results show that LINC00963 acts as an inducer of PCa metastasis by binding miR-542-3p, thereby promoting NOP2. This axis may have diagnostic and therapeutic potential for advanced PCa.

Citing Articles

Association between the expression of specific microRNAs and prostate cancer progression- a systematic review and meta-analysis.

Alrehaili J Front Oncol. 2025; 14:1481885.

PMID: 39991184 PMC: 11842264. DOI: 10.3389/fonc.2024.1481885.


MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration-Where Are We Now?.

Ferreira M, Morais M, Medeiros R, Teixeira A Pharmaceutics. 2024; 16(11).

PMID: 39598472 PMC: 11597238. DOI: 10.3390/pharmaceutics16111347.


NOP2 facilitates EZH2-mediated epithelial-mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression.

Yang Y, Fan H, Liu H, Lou X, Xiao N, Zhang C Cell Death Dis. 2024; 15(7):506.

PMID: 39013911 PMC: 11252406. DOI: 10.1038/s41419-024-06899-w.


The functions and mechanisms of RNA modification in prostate: Current status and future perspectives.

Zhang Z, Liu J, Wu Y, Gu Z, Zou L, Liu Y Front Genet. 2024; 15:1380746.

PMID: 38798700 PMC: 11116725. DOI: 10.3389/fgene.2024.1380746.


Nuclear protein NOP2 serves as a poor-prognosis predictor of LUAD and aggravates the malignancy of lung adenocarcinoma cells.

Qin W, Fei G, Zhou Q, Li Z, Li W, Wei P Funct Integr Genomics. 2024; 24(2):58.

PMID: 38489049 DOI: 10.1007/s10142-024-01337-8.


References
1.
Fanucchi S, Fok E, Dalla E, Shibayama Y, Borner K, Chang E . Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments. Nat Genet. 2018; 51(1):138-150. DOI: 10.1038/s41588-018-0298-2. View

2.
Zhou K, Li S, Du G, Fan Y, Wu P, Sun H . LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p. Onco Targets Ther. 2019; 12:7095-7109. PMC: 6730611. DOI: 10.2147/OTT.S208329. View

3.
Xu X, Hou J, Lv J, Huang Y, Pu J, Wang L . Overexpression of lncRNA GAS5 suppresses prostatic epithelial cell proliferation by regulating COX-2 in chronic non-bacterial prostatitis. Cell Cycle. 2019; 18(9):923-931. PMC: 6527275. DOI: 10.1080/15384101.2019.1593644. View

4.
Stone L . CRPC-specific gene therapy. Nat Rev Urol. 2019; 16(4):206-207. DOI: 10.1038/s41585-019-0165-7. View

5.
Li J, Shao W, Feng H . MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer. Biomed Pharmacother. 2018; 110:850-856. DOI: 10.1016/j.biopha.2018.11.104. View